Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Bartelink IH, et al. Among authors: dhawan m. Breast Cancer Res. 2017 Sep 11;19(1):107. doi: 10.1186/s13058-017-0896-4. Breast Cancer Res. 2017. PMID: 28893315 Free PMC article.
A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study.
Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. Aggarwal R, et al. Among authors: dhawan m. Urol Oncol. 2017 Apr;35(4):149.e7-149.e13. doi: 10.1016/j.urolonc.2016.11.005. Epub 2017 Feb 1. Urol Oncol. 2017. PMID: 28161323 Clinical Trial.
Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. Dhawan MS, et al. Clin Cancer Res. 2017 Nov 1;23(21):6400-6410. doi: 10.1158/1078-0432.CCR-17-0703. Epub 2017 Aug 8. Clin Cancer Res. 2017. PMID: 28790114 Clinical Trial.
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.
Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN. Terranova-Barberio M, et al. Among authors: dhawan m. Nat Commun. 2020 Jul 17;11(1):3584. doi: 10.1038/s41467-020-17414-y. Nat Commun. 2020. PMID: 32681091 Free PMC article. Clinical Trial.
A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN. Tsang ES, et al. Among authors: dhawan ms. Cancer Res Commun. 2022 Jul 1;2(7):570-576. doi: 10.1158/2767-9764.CRC-22-0028. eCollection 2022 Jul. Cancer Res Commun. 2022. PMID: 36923283 Free PMC article. Clinical Trial.
166 results